Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the ...

Bristol Myers Squibb’s Opdivo plus Yervoy gets US FDA nod to treat adult and pediatric patients with mismatch repair deficient colorectal cancer: Princeton, N.J. Thursday, April ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a comparative analysis ...

The ongoing COMPANION-002 trial has been evaluating the candidate, tovecimig (formerly CTX-009), alongside paclitaxel in ...

USA News Group News Commentary – As the Trump administration signals potential cuts to the National Institutes of Health (NIH ...

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase ...

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...